Table 5. Presentation features of the... | American Society of Hematology

Table 5.

Presentation features of the patients entered into the consolidation and maintenance therapy randomizations

Parameter	Value	Consolidation		Maintenance
Parameter	Value	Short (n = 185)	Long (n = 186)	IFN (n = 182)	None (n = 180)
Age	< 60	35	34	34	34
	60-69	111	112	106	106
	70-74	33	33	34	34
	75	6	7	8	6
Sex	Male	107	108	104	104
	Female	78	78	78	76
Type of AML	De novo	157	154	154	151
	Secondary	28	32	28	29
White blood count, × 10⁹/L	0-9	100	94	98	93
	10-99	69	74	70	68
	100	11	16	11	15
	Unknown	5	2	3	4
FAB type	M0	8	4	3	8
	M1	61	36	49	48
	M2	51	55	49	52
	M3	6	7	5	7
	M4	25	31	33	24
	M5	13	19	15	16
	M6	9	11	9	10
	Other/unknown	12	23	19	15
Cytogenetic group	Favorable	16	16	18	13
	Intermediate	126	133	127	125
	Adverse	7	7	4	11
	Unknown	36	30	33	31

Parameter	Value	Consolidation		Maintenance
Parameter	Value	Short (n = 185)	Long (n = 186)	IFN (n = 182)	None (n = 180)
Age	< 60	35	34	34	34
	60-69	111	112	106	106
	70-74	33	33	34	34
	75	6	7	8	6
Sex	Male	107	108	104	104
	Female	78	78	78	76
Type of AML	De novo	157	154	154	151
	Secondary	28	32	28	29
White blood count, × 10⁹/L	0-9	100	94	98	93
	10-99	69	74	70	68
	100	11	16	11	15
	Unknown	5	2	3	4
FAB type	M0	8	4	3	8
	M1	61	36	49	48
	M2	51	55	49	52
	M3	6	7	5	7
	M4	25	31	33	24
	M5	13	19	15	16
	M6	9	11	9	10
	Other/unknown	12	23	19	15
Cytogenetic group	Favorable	16	16	18	13
	Intermediate	126	133	127	125
	Adverse	7	7	4	11
	Unknown	36	30	33	31

IFN indicates interferon; for other abbreviations, see Table 1.